Li Auto, XPeng, Nio And Some Other Big Stocks Moving Higher In Today’s Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Oramed Pharma Shares Fall After Additional Data From Oral Insulin Study
Oramed Pharmaceuticals Inc (NASDAQ:ORMP) has announced additional data from its Phase 2 trial (ORA-D-N02) of oral insulin candidate (ORMD-0801) to reduce…
Oramed Announces Additional Safety, Efficacy Data From Phase 2 Clinical Trial Of ORMD-0801 For NASH; Achieved Primary Endpoint
Achieved primary endpoint of safety and tolerability in participants with Type 2 diabetes with NASH.
Oral insulin candidate demonstrates consistent trends across key secondary endpoints with reduction of liver fat,
Oramed Pharmaceuticals Q3 EPS $(0.18) Down From $(0.17) YoY
Oramed Pharmaceuticals (NASDAQ:ORMP) reported quarterly losses of $(0.18) per share. This is a 5.88 percent decrease over losses of $(0.17) per share from the same period last year.
Important Biotech Catalysts For September 13, 2022 – End Of The Day Summary
Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety…
Oramed Reports Top-Line Results From Phase 2 NASH Trial With Its ORMD-0801, Oral Insulin Candidate; Met Primary And Secondary Endpoint
Primary endpoint met: ORMD-0801 was safe and well tolerated
Secondary endpoint met: ORMD-0801 showed clinically meaningful reduction of liver fat from baseline at 12 weeks
Strong evidence for treatment of NASH using
Recap Of Tuesday’s Biotech Catalysts – End of The Day Summary
European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg…
Oramed Accomplishes 50 Percent Enrolment In Late-Stage Oral Insulin Study
Oramed Pharmaceuticals (NASDAQ: ORMP) has enrolled over 50 percent of the planned 450 patients for its international multicenter Phase 3 ORA-D-013-2 trial of oral insulin capsule, ORMD-0801, for the treatment of type 2 diabetes (T2D).
Oramed Reaches 50% Enrollment In Its Second Phase 3 Oral Insulin Trial
- ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol
- ORA-D-013-1, the larger of the two trials, completed enrollment with top line data expected January 2023